Experimental Drug Shows Promise Against NRAS-Driven Melanoma

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

Cutting-Edge Drug Shows Promise for Patients with NRAS-Driven Melanoma

Researchers found the drug daraxonrasib could be effective against an aggressive type of skin cancer, offering hope for patients with advanced disease who currently lack effective targeted options.